Table 2.
Reversal of MCT-Induced PAH by VIP, Bosentan, or Their Combination
| Measurements | Control, untreated | MCT + | P value (post hoc) | |||||
|---|---|---|---|---|---|---|---|---|
| 0 | VIP | Bosentan | VIP + Bosentan | * | † | ** | ||
| RV systolic pressure (mm Hg) | 24.3 ± 2.4 | 61.4 ± 4.8 | 33 ± 0.5 | 39 ± 1.2 | 26.0 ± 1.2 | < 0.05 | < 0.05 | < 0.05 |
| Arteriolar medial/luminal area | 0.76 ± 0.07 | 3.9 ± 0.51 | 1.68 ± 0.19 | 1.76 ± 0.19 | 0.79 ± 0.05 | < 0.05 | < 0.05 | < 0.05 |
| RV/(LV+septum) weight ratio | 0.26 ± 0.01 | 0.56 ± 0.03 | 0.51 ± 0.03 | 0.47 ± 0.07 | 0.34 ± 0.02 | NS | NS | < 0.05 |
| Lung inflammation (0-4) | 0.20 ± 0.17 | 3.0 ± 0.26 | 0.3 ± 0.21 | 1.2 ± 0.28 | 0.3 ± 0.33 | < 0.05 | < 0.05 | < 0.05 |
Therapy with either drug, or both together, was begun 3 weeks following MCT, i.e., after PH had fully developed. ANOVA: p < 0.0001
* MCT + VIP vs. MCT; † MCT + Bosentan vs. MCT; ** MCT + VIP + bosentan vs. MCT